SHIONOGI & CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7,489 JPY | 0.00% |
|
+1.97% | +10.16% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 445B 2.86B | Sales 2025 * | 422B 2.71B | Capitalization | 2,123B 13.63B |
|---|---|---|---|---|---|
| Net income 2024 * | 161B 1.04B | Net income 2025 * | 149B 956M | EV / Sales 2024 * | 3.71 x |
| Net cash position 2024 * | 473B 3.04B | Net cash position 2025 * | 566B 3.63B | EV / Sales 2025 * | 3.69 x |
| P/E ratio 2024 * |
13.4
x | P/E ratio 2025 * |
14.4
x | Employees | 5,680 |
| Yield 2024 * |
2.14% | Yield 2025 * |
2.08% | Free-Float | 88.4% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 week | +1.97% | ||
| Current month | +1.56% | ||
| 1 month | -0.15% | ||
| 3 months | +3.27% | ||
| 6 months | +5.79% | ||
| Current year | +10.16% |
1 week
7 316.00
7 555.00
1 month
7 062.007 555.00
Current year
6 741.008 137.00
1 year
5 718.008 137.00
3 years
5 438.008 439.00
5 years
4 379.008 439.00
10 years
1 838.008 439.00
| Managers | Title | Age | Since |
|---|---|---|---|
Isao Teshirogi
CEO | Chief Executive Officer | 64 | 82-03-31 |
Yuji Hosogai
DFI | Director of Finance/CFO | - | - |
Yasuetsu Imune
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hiroshi Ozaki
BRD | Director/Board Member | 74 | 19-05-31 |
Isao Teshirogi
CEO | Chief Executive Officer | 64 | 82-03-31 |
Takuko Sawada
BRD | Director/Board Member | 69 | 77-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.69% | 0 M€ | +11.43% | ||
| 2.51% | 0 M€ | +7.65% | - | |
| 1.07% | 0 M€ | +16.78% | ||
| 1.05% | 0 M€ | +13.64% | - | |
| 1.04% | 0 M€ | +13.17% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 7,489 | 0.00% | 541 800 |
| 24-05-09 | 7,489 | +1.24% | 748,100 |
| 24-05-08 | 7,397 | -0.23% | 639,700 |
| 24-05-07 | 7,414 | +0.95% | 736,900 |
| 24-05-02 | 7,344 | -0.61% | 409,000 |
Delayed Quote Japan Exchange, May 10, 2024 at 02:00 am EDT
More quotes
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products:
- prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.;
- OTC products: analgesic products, vitamins and tonics, etc.;
- diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
7,489
JPY
Average target price
7,782
JPY
Spread / Average Target
+3.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.16% | 13.64B | |
| +32.36% | 695B | |
| +26.51% | 568B | |
| -4.40% | 361B | |
| +19.46% | 330B | |
| +3.50% | 283B | |
| +17.11% | 239B | |
| +8.08% | 204B | |
| -7.61% | 198B | |
| +8.62% | 168B |
- Stock Market
- Equities
- 4507 Stock